Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Application of Radiolabeled Peptides in Tumor Imaging and Therapy Publisher Pubmed



Mohtavinejad N1 ; Shafiee Ardestani M1 ; Khalaj A2 ; Pormohammad A3 ; Najafi R4 ; Bitarafanrajabi A5, 6 ; Hajiramezanali M1 ; Amanlou M2
Authors

Source: Life Sciences Published:2020


Abstract

Scientists are looking for new therapies to cope with the rise in cancer worldwide. Since cancer cells overexpress peptide receptors and owing to small size, easy uptake by tumor cells, easy preparation, and with no toxicity, the use of radiolabeled peptides with high specificity and affinity for accurate imaging and therapy has attracted much attention. To develop an ideal imaging or treatment radiolabeled peptide, there are some aspects in the components of radiolabeled peptide including radionuclide, peptide, chelator, and spacer that should be considered. Some peptides, including somatostatin, RGD, neurotensin, bombesin, exendin, vasoactive intestinal peptide, and gastrin are currently under (pre)clinical investigations. Today, nanoparticles are suitable tools for targeting peptide for molecular imaging and therapy of tumors with low toxicity. This paper presents some essential aspects in developing a valuable radiolabeled peptide and some radiolabeled peptides with regard to their applications in tumor imaging and therapy in pre-clinical and clinical phases. © 2020
Other Related Docs
5. Breast Tumor Targeting in Mice Bearing 4T1 Tumor With Labeled Cxcr4 Antagonist Analogue, International Journal of Peptide Research and Therapeutics (2021)
8. Radiolabeled Peptides for Molecular Imaging of Apoptosis, Current Medicinal Chemistry (2020)
15. Oncolytic Virotherapy: Challenges and Solutions, Current Problems in Cancer (2021)
17. 99Mtc-Radiolabeled Ge11-Modified Peptide for Ovarian Tumor Targeting, DARU# Journal of Pharmaceutical Sciences (2017)
20. Rgd-Engineered Nanoparticles As an Innovative Drug Delivery System in Cancer Therapy, Journal of Drug Delivery Science and Technology (2023)